

## VI. CLAIMS

What is claimed is:

1. A composition comprising a kinase pathway inhibitor and an anti-prostate cancer compound.
2. The composition of claim 1, wherein the anti-prostate cancer compound is an antiandrogen.
3. The composition of claim 2, wherein the anti-androgen is Flutamide, Casodex, or Nilutamide.
4. The composition of claim 2, wherein the anti-androgen is Flutamide.
5. The composition of claim 2, wherein the concentration of the anti-androgen is less than or equal to 20  $\mu$ M.
6. The composition of claim 1, wherein the kinase pathway inhibitor comprises a MAP kinase inhibitor.
7. The composition of claim 6, wherein the MAP kinase pathway inhibitor comprises U0126.
8. The composition of claim 6, wherein the concentration of the MAP kinase pathway inhibitor is less than or equal to 100 $\mu$ M.
9. The composition of claim 1, wherein the kinase pathway inhibitor comprises a phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor.
10. The composition of claim 9, wherein the PI3K/Akt inhibitor is selected from the group consisting of SH-5, SH-6; 1L-6-hydroxymethyl-chiro-inositol 2(R)-2-O-methyl-3-O-octadecylcarbonate, SR13668, wortmannin, LY294002, and API-59.
11. The composition of claim 10, wherein the PI3K/Akt inhibitor is LY294002.
12. The composition of claim 9, wherein the concentration of the PI3k/Akt kinase pathway inhibitor is less than or equal to 20 $\mu$ M.
13. The composition of claim 1, wherein the anti-prostate cancer compound is less than or equal to 20 $\mu$ M.
14. The composition of claims 1-13, wherein the composition further comprises a pharmaceutically acceptable carrier.

15. A method of treating a subject with prostate cancer comprising administering the composition of claims 1-13.

16. The method of claim 15 wherein administering the composition comprises injecting the composition into the subject.

5 17. The method of claim 15, wherein administering the composition comprises taking the composition orally, taking by skin patch, or taking by subcutaneous injection.

18. A method of identifying an inhibitor of the MAP kinase pathway, comprising incubating a library of molecules with a cell comprising an activatable MAP kinase pathway and wherein the cell is also incubated with an antiandrogen, and selecting those molecules  
10 which inhibit the activation of the MAP kinase pathway.

19. A method of identifying a prostate cancer inhibitor comprising incubating a cell with hydroxyflutamide, incubating the cell with a potential inhibitor, and assaying the level of activation of a MAP kinase pathway.

20. The method of claim 19, wherein the cell is a DU145 cell.

15 21. A method of identifying a prostate cancer inhibitor comprising incubating a cell with hydroxyflutamide, incubating the cell with a potential inhibitor, and assaying the level of activation of a PI3K/Akt kinase pathway.

22. The method of claim 21, wherein the cell is a high passage LNCaP cell.

23. A method of reducing the number of prostate cancer cells in a sample comprising  
20 contacting the cells with the composition of claim 14.

24. A method of treating a patient with prostate cancer comprising administering the composition of claim 14.